Skip to content

Study · Randomized controlled trial · 2023

12 results

Abaloparatide dose-dependently increases bone mineral density in postmenopausal women with osteoporosis: a phase 2 study.

Matsumoto T, Sone T, Yamashita A, Inoue T

Journal of bone and mineral metabolism28 Jul 2023Cited by 3 (Europe PMC)

PMID37505256 (opens in a new tab)DOI10.1007/s00774-023-01455-6 (opens in a new tab)PepBankPUB-37505256
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In postmenopausal Japanese women with osteoporosis, abaloparatide 40 µg increased lumbar spine BMD significantly more than placebo.

    In plain wordsIn women with osteoporosis, abaloparatide 40 µg increased spine bone density more than placebo.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseLumbar spine BMD at 40 µg
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 µg daily · subcutaneous injection · 48 weeksAs given in this study (human).

    Measurements

    Lumbar spine BMD increase
    6.6%
    40 µg

    Source sentences

    Summary
    Increases in LS BMD with 40 and 80 µg abaloparatide were significantly higher than that with placebo (6.6% and 11.5%, respectively), with significant between-group differences for the abaloparatide groups (4.9%).
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled, dose-finding study of abaloparatide in postmenopausal Japanese women at high fracture risk.
    Summary · context
    The primary endpoint was the change in lumbar spine (LS) BMD from baseline at the last visit after daily subcutaneous injections of placebo or 40 or 80 µg abaloparatide.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In postmenopausal Japanese women with osteoporosis, abaloparatide 80 µg increased lumbar spine BMD significantly more than placebo.

    In plain wordsIn women with osteoporosis, abaloparatide 80 µg increased spine bone density more than placebo.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseLumbar spine BMD at 80 µg
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 µg daily · subcutaneous injection · 48 weeksAs given in this study (human).

    Measurements

    Lumbar spine BMD increase
    11.5%
    80 µg

    Source sentences

    Summary
    Increases in LS BMD with 40 and 80 µg abaloparatide were significantly higher than that with placebo (6.6% and 11.5%, respectively), with significant between-group differences for the abaloparatide groups (4.9%).
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled, dose-finding study of abaloparatide in postmenopausal Japanese women at high fracture risk.
    Summary · context
    The primary endpoint was the change in lumbar spine (LS) BMD from baseline at the last visit after daily subcutaneous injections of placebo or 40 or 80 µg abaloparatide.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In postmenopausal Japanese women with osteoporosis, lumbar spine BMD increased significantly more with abaloparatide 80 µg than 40 µg.

    In plain wordsIn women with osteoporosis, abaloparatide 80 µg increased spine bone density more than 40 µg.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseLumbar spine BMD dose comparison
    Study

    n: not reported in source

    Comparator
    Abaloparatide 40 µg
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 µg daily · subcutaneous injection · 48 weeksAs given in this study (human).

    Measurements

    Between-dose difference
    4.9%
    80 versus 40 µg

    Source sentences

    Summary
    Increases in LS BMD with 40 and 80 µg abaloparatide were significantly higher than that with placebo (6.6% and 11.5%, respectively), with significant between-group differences for the abaloparatide groups (4.9%).
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled, dose-finding study of abaloparatide in postmenopausal Japanese women at high fracture risk.
    Summary · context
    The primary endpoint was the change in lumbar spine (LS) BMD from baseline at the last visit after daily subcutaneous injections of placebo or 40 or 80 µg abaloparatide.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In postmenopausal Japanese women with osteoporosis, total hip BMD increased 1.6% with abaloparatide 40 µg and 0.4% with placebo.

    In plain wordsIn women with osteoporosis, hip bone density increased 1.6% with abaloparatide 40 µg and 0.4% with placebo.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTotal hip BMD at 40 µg
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 µg daily · subcutaneous injection · 48 weeksAs given in this study (human).

    Measurements

    Total hip BMD increase
    1.6%
    40 µg
    Total hip BMD increase
    0.4%
    placebo

    Source sentences

    Summary
    TH BMD increased by 0.4%, 1.6%, and 2.9% and FN BMD increased by 0.6%, 1.5%, and 2.4% in the placebo and 40 and 80 µg abaloparatide groups, respectively.
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled, dose-finding study of abaloparatide in postmenopausal Japanese women at high fracture risk.
    Summary · context
    The primary endpoint was the change in lumbar spine (LS) BMD from baseline at the last visit after daily subcutaneous injections of placebo or 40 or 80 µg abaloparatide.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In postmenopausal Japanese women with osteoporosis, total hip BMD increased 2.9% with abaloparatide 80 µg and 0.4% with placebo.

    In plain wordsIn women with osteoporosis, hip bone density increased 2.9% with abaloparatide 80 µg and 0.4% with placebo.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTotal hip BMD at 80 µg
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 µg daily · subcutaneous injection · 48 weeksAs given in this study (human).

    Measurements

    Total hip BMD increase
    2.9%
    80 µg
    Total hip BMD increase
    0.4%
    placebo

    Source sentences

    Summary
    TH BMD increased by 0.4%, 1.6%, and 2.9% and FN BMD increased by 0.6%, 1.5%, and 2.4% in the placebo and 40 and 80 µg abaloparatide groups, respectively.
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled, dose-finding study of abaloparatide in postmenopausal Japanese women at high fracture risk.
    Summary · context
    The primary endpoint was the change in lumbar spine (LS) BMD from baseline at the last visit after daily subcutaneous injections of placebo or 40 or 80 µg abaloparatide.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In postmenopausal Japanese women with osteoporosis, femoral neck BMD increased 1.5% with abaloparatide 40 µg and 0.6% with placebo.

    In plain wordsIn women with osteoporosis, femoral neck bone density increased 1.5% with abaloparatide 40 µg and 0.6% with placebo.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFemoral neck BMD at 40 µg
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 µg daily · subcutaneous injection · 48 weeksAs given in this study (human).

    Measurements

    Femoral neck BMD increase
    1.5%
    40 µg
    Femoral neck BMD increase
    0.6%
    placebo

    Source sentences

    Summary
    TH BMD increased by 0.4%, 1.6%, and 2.9% and FN BMD increased by 0.6%, 1.5%, and 2.4% in the placebo and 40 and 80 µg abaloparatide groups, respectively.
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled, dose-finding study of abaloparatide in postmenopausal Japanese women at high fracture risk.
    Summary · context
    The primary endpoint was the change in lumbar spine (LS) BMD from baseline at the last visit after daily subcutaneous injections of placebo or 40 or 80 µg abaloparatide.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In postmenopausal Japanese women with osteoporosis, femoral neck BMD increased 2.4% with abaloparatide 80 µg and 0.6% with placebo.

    In plain wordsIn women with osteoporosis, femoral neck bone density increased 2.4% with abaloparatide 80 µg and 0.6% with placebo.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFemoral neck BMD at 80 µg
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 µg daily · subcutaneous injection · 48 weeksAs given in this study (human).

    Measurements

    Femoral neck BMD increase
    2.4%
    80 µg
    Femoral neck BMD increase
    0.6%
    placebo

    Source sentences

    Summary
    TH BMD increased by 0.4%, 1.6%, and 2.9% and FN BMD increased by 0.6%, 1.5%, and 2.4% in the placebo and 40 and 80 µg abaloparatide groups, respectively.
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled, dose-finding study of abaloparatide in postmenopausal Japanese women at high fracture risk.
    Summary · context
    The primary endpoint was the change in lumbar spine (LS) BMD from baseline at the last visit after daily subcutaneous injections of placebo or 40 or 80 µg abaloparatide.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In postmenopausal Japanese women with osteoporosis, abaloparatide 40 µg rapidly increased serum PINP by 67.3%.

    In plain wordsIn women with osteoporosis, the bone formation marker PINP increased 67.3% from baseline with abaloparatide 40 µg.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseSerum PINP at 40 µg
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 µg daily · subcutaneous injection · 48 weeksAs given in this study (human).

    Measurements

    Serum PINP increase
    67.3%
    40 µg

    Source sentences

    Summary
    Serum PINP rapidly increased by 67.3% and 140.7% and serum CTX slowly increased by 16.4% and 34.5% in the 40 and 80 µg abaloparatide groups, respectively.
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled, dose-finding study of abaloparatide in postmenopausal Japanese women at high fracture risk.
    Summary · context
    The primary endpoint was the change in lumbar spine (LS) BMD from baseline at the last visit after daily subcutaneous injections of placebo or 40 or 80 µg abaloparatide.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In postmenopausal Japanese women with osteoporosis, abaloparatide 80 µg rapidly increased serum PINP by 140.7%.

    In plain wordsIn women with osteoporosis, the bone formation marker PINP increased 140.7% from baseline with abaloparatide 80 µg.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseSerum PINP at 80 µg
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 µg daily · subcutaneous injection · 48 weeksAs given in this study (human).

    Measurements

    Serum PINP increase
    140.7%
    80 µg

    Source sentences

    Summary
    Serum PINP rapidly increased by 67.3% and 140.7% and serum CTX slowly increased by 16.4% and 34.5% in the 40 and 80 µg abaloparatide groups, respectively.
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled, dose-finding study of abaloparatide in postmenopausal Japanese women at high fracture risk.
    Summary · context
    The primary endpoint was the change in lumbar spine (LS) BMD from baseline at the last visit after daily subcutaneous injections of placebo or 40 or 80 µg abaloparatide.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In postmenopausal Japanese women with osteoporosis, abaloparatide 40 µg slowly increased serum CTX by 16.4%.

    In plain wordsIn women with osteoporosis, the bone resorption marker CTX increased 16.4% from baseline with abaloparatide 40 µg.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseSerum CTX at 40 µg
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 µg daily · subcutaneous injection · 48 weeksAs given in this study (human).

    Measurements

    Serum CTX increase
    16.4%
    40 µg

    Source sentences

    Summary
    Serum PINP rapidly increased by 67.3% and 140.7% and serum CTX slowly increased by 16.4% and 34.5% in the 40 and 80 µg abaloparatide groups, respectively.
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled, dose-finding study of abaloparatide in postmenopausal Japanese women at high fracture risk.
    Summary · context
    The primary endpoint was the change in lumbar spine (LS) BMD from baseline at the last visit after daily subcutaneous injections of placebo or 40 or 80 µg abaloparatide.
  11. 11HumanRandomized controlled trialEfficacy outcome

    In postmenopausal Japanese women with osteoporosis, abaloparatide 80 µg slowly increased serum CTX by 34.5%.

    In plain wordsIn women with osteoporosis, the bone resorption marker CTX increased 34.5% from baseline with abaloparatide 80 µg.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseSerum CTX at 80 µg
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 µg daily · subcutaneous injection · 48 weeksAs given in this study (human).

    Measurements

    Serum CTX increase
    34.5%
    80 µg

    Source sentences

    Summary
    Serum PINP rapidly increased by 67.3% and 140.7% and serum CTX slowly increased by 16.4% and 34.5% in the 40 and 80 µg abaloparatide groups, respectively.
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled, dose-finding study of abaloparatide in postmenopausal Japanese women at high fracture risk.
    Summary · context
    The primary endpoint was the change in lumbar spine (LS) BMD from baseline at the last visit after daily subcutaneous injections of placebo or 40 or 80 µg abaloparatide.
  12. 12HumanRandomized controlled trialSafety outcome

    In postmenopausal Japanese women with osteoporosis, adverse events were more frequent with abaloparatide but were mild to moderate and not dose dependent.

    In plain wordsIn women with osteoporosis, abaloparatide caused more adverse events than placebo. Events were mild to moderate, without dose dependence.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseAdverse events
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    40 or 80 µg daily · subcutaneous injection · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    Although more adverse events were observed in the abaloparatide groups, they were mild to moderate and not dose dependent.
    2 context sentences
    Summary · context
    Randomized, double-blind, placebo-controlled, dose-finding study of abaloparatide in postmenopausal Japanese women at high fracture risk.
    Summary · context
    The primary endpoint was the change in lumbar spine (LS) BMD from baseline at the last visit after daily subcutaneous injections of placebo or 40 or 80 µg abaloparatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.